FDC Q1 Revenue at Rs 6.48 Billion, Margins Dip Slightly

08 Aug 2025 CW Team

FDC Limited has reported a steady performance for the quarter ended 30 June 2025 (Q1 FY26), with operating revenue of Rs 6.48 billion, reflecting a year-on-year (YoY) growth of 1.6 per cent.

The India formulation business recorded revenue of Rs 5.79 billion, showing a 5.6 per cent YoY rise and contributing 90 per cent to total consolidated sales. The API segment also delivered modest growth of 3.3 per cent YoY, with sales of Rs 260 million. However, export formulations dropped 33.8 per cent YoY to Rs 420 million, while emerging market revenue declined 39 per cent YoY to Rs 260 million due to supply disruptions.

The US business showed early signs of recovery, with Rs 116 million in sales during Q1 FY26, representing a 106 per cent YoY growth in direct supplies. This growth follows the resolution of recall-related issues and updated API impurity standards clarified by the US FDA. Despite this progress, overall US business revenue fell 22.2 per cent YoY due to lower profit share from partners caused by reduced sales in FY25.

FDC’s EBITDA for the quarter stood at Rs 1.4 billion, with a margin of 21.6 per cent, down from 23 per cent in the previous year. The drop is mainly due to increased strategic expenses, notably a 271.4 per cent YoY surge in R&D expenditure to Rs 85 million and higher employee costs linked to field force expansion and ORS manufacturing capacity enhancements.

Business Performance Summary – Q1 FY26 (Rs crore):

Net Sales: Rs 648 crore | 1.6% YoY growth
India Formulations: Rs 579 crore | 5.6% YoY growth
US Formulations: Rs 16 crore | -22.2% YoY decline
Emerging Markets: Rs 26 crore | -39.3% YoY decline
API Sales: Rs 26 crore | 3.3% YoY growth

According to IQVIA secondary sales data (MAT June 30, 2025), FDC outpaced the Indian Pharmaceutical Market (IPM) with 10.8 per cent growth versus 8.0 per cent for IPM. Its flagship brand, Electral, climbed to 14th place in IPM rankings, up from 18th the previous year. Electral also became the fastest-growing product among IPM’s top 20 and the first FDC brand to cross Rs 6 billion in IPM sales.

Export formulation sales were Rs 420 million, accounting for 6 per cent of total sales, while the API business represented 4 per cent with Rs 260 million in revenue.

Despite short-term supply challenges in emerging markets, FDC maintains a healthy order pipeline and expects improved execution in subsequent quarters.

FDC Limited has reported a steady performance for the quarter ended 30 June 2025 (Q1 FY26), with operating revenue of Rs 6.48 billion, reflecting a year-on-year (YoY) growth of 1.6 per cent.The India formulation business recorded revenue of Rs 5.79 billion, showing a 5.6 per cent YoY rise and contributing 90 per cent to total consolidated sales. The API segment also delivered modest growth of 3.3 per cent YoY, with sales of Rs 260 million. However, export formulations dropped 33.8 per cent YoY to Rs 420 million, while emerging market revenue declined 39 per cent YoY to Rs 260 million due to supply disruptions.The US business showed early signs of recovery, with Rs 116 million in sales during Q1 FY26, representing a 106 per cent YoY growth in direct supplies. This growth follows the resolution of recall-related issues and updated API impurity standards clarified by the US FDA. Despite this progress, overall US business revenue fell 22.2 per cent YoY due to lower profit share from partners caused by reduced sales in FY25.FDC’s EBITDA for the quarter stood at Rs 1.4 billion, with a margin of 21.6 per cent, down from 23 per cent in the previous year. The drop is mainly due to increased strategic expenses, notably a 271.4 per cent YoY surge in R&D expenditure to Rs 85 million and higher employee costs linked to field force expansion and ORS manufacturing capacity enhancements.Business Performance Summary – Q1 FY26 (Rs crore):Net Sales: Rs 648 crore | 1.6% YoY growthIndia Formulations: Rs 579 crore | 5.6% YoY growthUS Formulations: Rs 16 crore | -22.2% YoY declineEmerging Markets: Rs 26 crore | -39.3% YoY declineAPI Sales: Rs 26 crore | 3.3% YoY growthAccording to IQVIA secondary sales data (MAT June 30, 2025), FDC outpaced the Indian Pharmaceutical Market (IPM) with 10.8 per cent growth versus 8.0 per cent for IPM. Its flagship brand, Electral, climbed to 14th place in IPM rankings, up from 18th the previous year. Electral also became the fastest-growing product among IPM’s top 20 and the first FDC brand to cross Rs 6 billion in IPM sales.Export formulation sales were Rs 420 million, accounting for 6 per cent of total sales, while the API business represented 4 per cent with Rs 260 million in revenue.Despite short-term supply challenges in emerging markets, FDC maintains a healthy order pipeline and expects improved execution in subsequent quarters.

Infrastructure Urban

04 Aug 2026

TCC Concept Reports 480% Revenue Growth in Q1FY27

TCC Concept has reported strong financial performance for the first quarter of FY27, with revenue from operations rising 480% year-on-year to Rs 1,283 million.The company’s EBITDA increased 158% year-on-year to Rs 463 million, with an EBITDA margin of 36.1%. Profit after tax (PAT) grew 34% year-on-year to Rs 126 million during the quarter.The growth was supported by continued execution across TCC’s integrated ecosystem spanning consumer commerce, supply chain, digital infrastructure, cloud, PropTech and AI-led platforms.Pepperfry continued to strengthen its omnichannel expansion stra..

Real Estate

04 Aug 2026

ANHAD Developers Appoints Akash Lakhina as Sales Head

ANHAD Developers has appointed Akash Lakhina as Head of Sales, Marketing and CRM as the company strengthens its leadership team ahead of its entry into Gurugram’s premium residential market.The appointment follows Adil Altaf taking charge as CEO of the group’s real estate vertical. Lakhina will be responsible for driving the company’s sales, marketing and customer relationship initiatives for its upcoming luxury developments.With nearly three decades of professional experience, Lakhina brings expertise across multiple industries, including over a decade in luxury real estate. His experie..

Real Estate

04 Aug 2026

BXB Estates Records AED 110 Million Luxury Villa Sale in Dubai

BXB Estates has completed a record AED 110 million residential transaction at Jumeirah Golf Estates, marking the highest-value residential sale in the history of one of Dubai’s most prestigious communities.The transaction, negotiated by Alfie Tabrez, Managing Partner, BXB Estates, surpasses the previous record of AED 58 million for a completed ready villa.The six-bedroom luxury residence features a built-up area of 21,714 sq ft on a 15,873 sq ft plot. The property includes nine bathrooms, four living lounges, a home office, bar lounge, private cinema and rooftop terrace. Its wellness facilit..